Cargando…

NMD Microarray Analysis for Rapid Genome-Wide Screen of Mutated Genes in Cancer

Gene mutations play a critical role in cancer development and progression, and their identification offers possibilities for accurate diagnostics and therapeutic targeting. Finding genes undergoing mutations is challenging and slow, even in the post-genomic era. A new approach was recently developed...

Descripción completa

Detalles Bibliográficos
Autores principales: Wolf, Maija, Edgren, Henrik, Muggerud, Aslaug, Kilpinen, Sami, Huusko, Pia, Sørlie, Therese, Mousses, Spyro, Kallioniemi, Olli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2005
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4617499/
https://www.ncbi.nlm.nih.gov/pubmed/16037637
http://dx.doi.org/10.1155/2005/478316
_version_ 1782396806864306176
author Wolf, Maija
Edgren, Henrik
Muggerud, Aslaug
Kilpinen, Sami
Huusko, Pia
Sørlie, Therese
Mousses, Spyro
Kallioniemi, Olli
author_facet Wolf, Maija
Edgren, Henrik
Muggerud, Aslaug
Kilpinen, Sami
Huusko, Pia
Sørlie, Therese
Mousses, Spyro
Kallioniemi, Olli
author_sort Wolf, Maija
collection PubMed
description Gene mutations play a critical role in cancer development and progression, and their identification offers possibilities for accurate diagnostics and therapeutic targeting. Finding genes undergoing mutations is challenging and slow, even in the post-genomic era. A new approach was recently developed by Noensie and Dietz to prioritize and focus the search, making use of nonsense-mediated mRNA decay (NMD) inhibition and microarray analysis (NMD microarrays) in the identification of transcripts containing nonsense mutations. We combined NMD microarrays with array-based CGH (comparative genomic hybridization) in order to identify inactivation of tumor suppressor genes in cancer. Such a “mutatomics” screening of prostate cancer cell lines led to the identification of inactivating mutations in the EPHB2 gene. Up to 8% of metastatic uncultured prostate cancers also showed mutations of this gene whose loss of function may confer loss of tissue architecture. NMD microarray analysis could turn out to be a powerful research method to identify novel mutated genes in cancer cell lines, providing targets that could then be further investigated for their clinical relevance and therapeutic potential.
format Online
Article
Text
id pubmed-4617499
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher IOS Press
record_format MEDLINE/PubMed
spelling pubmed-46174992016-01-12 NMD Microarray Analysis for Rapid Genome-Wide Screen of Mutated Genes in Cancer Wolf, Maija Edgren, Henrik Muggerud, Aslaug Kilpinen, Sami Huusko, Pia Sørlie, Therese Mousses, Spyro Kallioniemi, Olli Cell Oncol Review Gene mutations play a critical role in cancer development and progression, and their identification offers possibilities for accurate diagnostics and therapeutic targeting. Finding genes undergoing mutations is challenging and slow, even in the post-genomic era. A new approach was recently developed by Noensie and Dietz to prioritize and focus the search, making use of nonsense-mediated mRNA decay (NMD) inhibition and microarray analysis (NMD microarrays) in the identification of transcripts containing nonsense mutations. We combined NMD microarrays with array-based CGH (comparative genomic hybridization) in order to identify inactivation of tumor suppressor genes in cancer. Such a “mutatomics” screening of prostate cancer cell lines led to the identification of inactivating mutations in the EPHB2 gene. Up to 8% of metastatic uncultured prostate cancers also showed mutations of this gene whose loss of function may confer loss of tissue architecture. NMD microarray analysis could turn out to be a powerful research method to identify novel mutated genes in cancer cell lines, providing targets that could then be further investigated for their clinical relevance and therapeutic potential. IOS Press 2005 2005-07-21 /pmc/articles/PMC4617499/ /pubmed/16037637 http://dx.doi.org/10.1155/2005/478316 Text en Copyright © 2005 Hindawi Publishing Corporation and the authors.
spellingShingle Review
Wolf, Maija
Edgren, Henrik
Muggerud, Aslaug
Kilpinen, Sami
Huusko, Pia
Sørlie, Therese
Mousses, Spyro
Kallioniemi, Olli
NMD Microarray Analysis for Rapid Genome-Wide Screen of Mutated Genes in Cancer
title NMD Microarray Analysis for Rapid Genome-Wide Screen of Mutated Genes in Cancer
title_full NMD Microarray Analysis for Rapid Genome-Wide Screen of Mutated Genes in Cancer
title_fullStr NMD Microarray Analysis for Rapid Genome-Wide Screen of Mutated Genes in Cancer
title_full_unstemmed NMD Microarray Analysis for Rapid Genome-Wide Screen of Mutated Genes in Cancer
title_short NMD Microarray Analysis for Rapid Genome-Wide Screen of Mutated Genes in Cancer
title_sort nmd microarray analysis for rapid genome-wide screen of mutated genes in cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4617499/
https://www.ncbi.nlm.nih.gov/pubmed/16037637
http://dx.doi.org/10.1155/2005/478316
work_keys_str_mv AT wolfmaija nmdmicroarrayanalysisforrapidgenomewidescreenofmutatedgenesincancer
AT edgrenhenrik nmdmicroarrayanalysisforrapidgenomewidescreenofmutatedgenesincancer
AT muggerudaslaug nmdmicroarrayanalysisforrapidgenomewidescreenofmutatedgenesincancer
AT kilpinensami nmdmicroarrayanalysisforrapidgenomewidescreenofmutatedgenesincancer
AT huuskopia nmdmicroarrayanalysisforrapidgenomewidescreenofmutatedgenesincancer
AT sørlietherese nmdmicroarrayanalysisforrapidgenomewidescreenofmutatedgenesincancer
AT moussesspyro nmdmicroarrayanalysisforrapidgenomewidescreenofmutatedgenesincancer
AT kallioniemiolli nmdmicroarrayanalysisforrapidgenomewidescreenofmutatedgenesincancer